Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor

The outlook for T-cell malignancies remain poor due to the lack of effective therapeutic options. Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical trials for B-cell malignancies, however, designing CARs for T-cell based disease remain a challenge due to the shared...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Chen, K H, Wada, M, Pinz, K G, Liu, H, Lin, K-W, Jares, A, Firor, A E, Shuai, X, Salman, H, Golightly, M, Lan, F, Senzel, L, Leung, E L, Jiang, X, Ma, Y
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5629371/
https://ncbi.nlm.nih.gov/pubmed/28074066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2017.8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados